Single-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Sosei Heptares with the potential to simultaneously address positive, negative and cognitive symptoms of schizophreniaSosei Heptares will receive EUR 25 million upfront from Boehringer Ingelheim and is eligible for an option exercise payment of EUR 60 million and further milestone payments totaling up to EUR 670 million plus tiered royalties Ingelheim, Germany, Tokyo, Japan and Cambridge, UK,
Dr. Jeffrey Lieberman: World-Leading Schizophrenia Expert Dr. Jeffrey A. Lieberman Unravels the Mysteries of Schizophrenia on The People's Pharmacy finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
NEW YORK, NY / ACCESSWIRE / February 21, 2024 / Millions of Americans live with schizophrenia, a complex and long misunderstood behavioral brain disorder. Yet, today's medical advancements offer not only effective treatment, but also the potential for early intervention and prevention.World-leading schizophrenia exp.